Lupin has received USFDA approval to market Lurasidone Hydrochloride tablets in US markets. The drug is used in the treatment of schizophrenia and will be marketed in strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.
The drug is a generic version of Sunovion Pharmaceuticals’ Latuda tablets which according to market estimates has sales of around $ 3,217.3 million in the US market.
Company Profile : Lupin Ltd
Leave a Reply